COPD Special Report: The Year in Review

Slideshow

New GOLD guidelines, strategies, and challenges highlighted the key developments for primary care physicians in 2019.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Related Content
Roche's Investigational Anti-IL-33/ST2 Antibody / image credit ©Sundry Photography/stock.adobe.com

Roche's Investigational Anti-IL-33/ST2 Antibody for COPD Misses Phase 3 Primary Endpoint

Grace Halsey
September 3rd 2025
Article
Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD / image credit courtesy of Upstream Bio

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD

Grace Halsey
September 3rd 2025
Article
/ image credit ©alesmunt/stock.adobe.com

Sanofi, Regeneron's IL-33 mAb Misses Primary Endpoint in Late-Stage COPD Trial

Grace Halsey
September 3rd 2025
Article
Dupilumab Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study / image courtesy of ResearchGate

Dupilumab for Severe COPD Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study

Grace Halsey
September 3rd 2025
Article
Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype / image credit ©Waldenmarus/stock.adobe.com

Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype

Grace Halsey
September 3rd 2025
Article
Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD / image credit ©cpt88studio/stock.adobe.com

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD

Grace Halsey
September 3rd 2025
Article
© 2025 MJH Life Sciences

All rights reserved.